NEUROCRINE BIOSCIENCES INC's ticker is and the CUSIP is 64125CAD1. A total of 37 filers reported holding NEUROCRINE BIOSCIENCES INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $55,918 | +4.6% | 31,000 | 0.0% | 0.00% | – |
| Q4 2023 | $53,444 | +16.2% | 31,000 | 0.0% | 0.00% | – |
| Q3 2023 | $45,989 | +16.6% | 31,000 | 0.0% | 0.00% | – |
| Q2 2023 | $39,448 | -5.1% | 31,000 | 0.0% | 0.00% | – |
| Q1 2023 | $41,587 | -14.9% | 31,000 | 0.0% | 0.00% | – |
| Q4 2022 | $48,872 | +13.7% | 31,000 | 0.0% | 0.00% | – |
| Q3 2022 | $43,000 | +4.9% | 31,000 | 0.0% | 0.00% | – |
| Q2 2022 | $41,000 | – | 31,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SSI INVESTMENT MANAGEMENT LLC | 7,440,000 | $10,058,000 | 0.84% |
| SHENKMAN CAPITAL MANAGEMENT INC | 4,121,000 | $5,579,000 | 0.72% |
| Baker Brothers Advisors | 53,270,000 | $71,994,000 | 0.46% |
| LINDEN ADVISORS LP | 11,675,000 | $15,814,000 | 0.36% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 11,558,000 | $15,650,000 | 0.34% |
| AQR Arbitrage LLC | 20,000,000 | $27,077,000 | 0.34% |
| CSS LLC/IL | 3,455,000 | $4,675,000 | 0.28% |
| RWC Asset Management LLP | 4,000,000 | $5,396,000 | 0.25% |
| MACKAY SHIELDS LLC | 21,460,000 | $29,043,000 | 0.21% |
| Calamos Advisors LLC | 24,105,000 | $32,660,000 | 0.20% |